PCL
MCID: PLS016
MIFTS: 53

Plasma Cell Leukemia (PCL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Plasma Cell Leukemia

MalaCards integrated aliases for Plasma Cell Leukemia:

Name: Plasma Cell Leukemia 12 52 58 54 15 17
Leukemia, Plasma Cell 52 43 71
Plasma Cell Leukaemia 12 32
Plasmacytic Leukaemia 12
Plasmacytic Leukemia 12
Pcl 58

Characteristics:

Orphanet epidemiological data:

58
plasma cell leukemia
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult,Elderly; Age of death: adult,elderly;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:9513
ICD9CM 34 203.1
MeSH 43 D007952
NCIt 49 C3180
SNOMED-CT 67 128922003 95210003
ICD10 32 C90.1
ICD10 via Orphanet 33 C90.1
UMLS via Orphanet 72 C0023484
Orphanet 58 ORPHA454714
UMLS 71 C0023484

Summaries for Plasma Cell Leukemia

NIH Rare Diseases : 52 Plasma cell leukemia (PCL) is a rare and aggressive form of multiple myeloma that involves high levels of plasma cells circulating in the peripheral blood. The signs and symptoms of PCL include aggressive clinical features, such as extramedullary disease, bone marrow failure, advanced stage disease and expression of distinct immunophenotypic markers . Different types of treatments are available for patients with PCL. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials . For detailed information on the available treatment options, please visit the following link. http://www.cancer.gov/cancertopics/pdq/treatment/myeloma/Patient/page4

MalaCards based summary : Plasma Cell Leukemia, also known as leukemia, plasma cell, is related to leukemia and peripheral t-cell lymphoma. An important gene associated with Plasma Cell Leukemia is CCND1 (Cyclin D1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Hematinics and Epoetin alfa have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A plasma cell neoplasm that is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count.

Wikipedia : 74 Plasma cell leukemia (PCL) is a plasma cell dyscrasia, i.e. a disease involving the malignant... more...

Related Diseases for Plasma Cell Leukemia

Diseases related to Plasma Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 401)
# Related Disease Score Top Affiliating Genes
1 leukemia 31.3 NRAS MYC KRAS CDKN2A CCND1 BCL10
2 peripheral t-cell lymphoma 30.6 NCAM1 FGFR3 CD38 CCND1
3 plasmacytoma 30.3 NCAM1 MYC IRF4 IL6 CDKN2A CD38
4 lymphoplasmacytic lymphoma 30.3 IRF4 CD40 CCND1
5 plasma cell neoplasm 30.3 NCAM1 MYC MAF IRF4 IL6 FGFR3
6 central nervous system lymphoma 30.2 MYC IL6 CDKN2A
7 prolymphocytic leukemia 30.2 MYC CD38 CCND1
8 extramedullary plasmacytoma 30.2 NCAM1 IRF4 IL6 CD38 CCND1
9 serous cystadenocarcinoma 30.2 NRAS KRAS CDKN2A
10 cervical adenocarcinoma 30.2 MYC KRAS CDKN2A
11 exanthem 30.1 KRAS IL6 IFNA1
12 marginal zone b-cell lymphoma 30.0 IRF4 CD38 CCND1 BCL10
13 castleman disease 30.0 IL6 IFNA1 ICAM1
14 colorectal adenocarcinoma 30.0 MYC KRAS CDKN2A CD44 CCND1
15 pheochromocytoma 29.8 NCAM1 MYC IL6 CDKN2A CCND1
16 ovarian serous cystadenocarcinoma 29.8 NRAS MYC KRAS CDKN2A CCND1
17 adult t-cell leukemia 29.8 MYC IRF4 IFNA1 ICAM1 CDKN2A
18 myeloma, multiple 29.7 NRAS NCAM1 MYC MAF KRAS IRF4
19 essential thrombocythemia 29.6 MYC KRAS IL6 IFNA1 CCND1
20 lymphoma, mucosa-associated lymphoid type 29.6 MYC IRF4 CD40 CCND1 BCL10
21 glioblastoma multiforme 29.6 NRAS MYC KRAS IL6 IFNA1 ICAM1
22 immune deficiency disease 29.5 IRF4 IL6 IFNA1 CD40 CD38
23 suppression of tumorigenicity 12 29.4 NCAM1 MYC KRAS IL6 CDKN2A CD44
24 monoclonal gammopathy of uncertain significance 29.4 NCAM1 MYC MAF IRF4 IL6 FGFR3
25 t-cell lymphoblastic leukemia/lymphoma 29.3 MYC IRF4 ICAM1 CD40 CCND3 CCND1
26 cervical cancer 29.1 TP73 MYC IL6 FGFR3 CDKN2A CD44
27 leukemia, chronic myeloid 28.9 NRAS MYC KRAS ITGB1 IRF4 IFNA1
28 melanoma 28.7 NRAS MYC MIR181A1 KRAS IFNA1 ICAM1
29 mantle cell lymphoma 28.6 MYC IL6 CDKN2A CD44 CD40 CCND3
30 lung cancer susceptibility 3 28.6 TP73 NRAS MYC KRAS ITGB1 IL6
31 sarcoma 28.5 NRAS MYC KRAS ITGB1 IL6 IFNA1
32 b-cell lymphoma 28.3 MYC MIR181A1 IRF4 CDKN2A CD44 CD40
33 leukemia, acute myeloid 28.0 NRAS NCAM1 MYC MIR181A1 KRAS IL6
34 diffuse large b-cell lymphoma 28.0 MYC MIR181A1 IRF4 IL6 CDKN2A CD40
35 hepatocellular carcinoma 27.8 TP73 NRAS MYC MIR181A1 KRAS ITGB1
36 burkitt lymphoma 27.8 TP73 MYC IRF4 IL6 IFNA1 ICAM1
37 lymphoma 27.8 NRAS MYC ITGB1 IRF4 IL6 CDKN2A
38 ovarian cancer 27.4 TP73 MYC KRAS ITGB1 IL6 IFNA1
39 leukemia, chronic lymphocytic 27.0 NRAS NCAM1 MYC MIR181A1 KRAS IRF4
40 lung cancer 27.0 TP73 NRAS NCAM1 MYC MIR181A1 KRAS
41 colorectal cancer 26.9 TP73 NRAS NCAM1 MYC MIR181A1 KRAS
42 lymphoma, non-hodgkin, familial 26.8 NRAS NCAM1 MYC MIR181A1 ITGB1 IRF4
43 lymphatic malformation 1 11.5
44 hereditary lymphedema i 11.2
45 epidermolytic nevus 10.6 NRAS FGFR3
46 blastic plasmacytoid dendritic cell 10.5 NCAM1 MYC
47 primary cutaneous marginal zone b-cell lymphoma 10.5 IRF4 BCL10
48 bowenoid papulosis 10.5 CDKN2A CCND1
49 esophagus verrucous carcinoma 10.5 CDKN2A CCND1
50 trachea carcinoma in situ 10.5 KRAS CDKN2A

Graphical network of the top 20 diseases related to Plasma Cell Leukemia:



Diseases related to Plasma Cell Leukemia

Symptoms & Phenotypes for Plasma Cell Leukemia

GenomeRNAi Phenotypes related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.98 KRAS
2 Decreased viability GR00055-A-2 9.98 KRAS
3 Decreased viability GR00055-A-3 9.98 KRAS
4 Decreased viability GR00106-A-0 9.98 KRAS
5 Decreased viability GR00221-A-1 9.98 CDKN2A FGFR3 KRAS MYC NRAS
6 Decreased viability GR00221-A-2 9.98 FGFR3 KRAS
7 Decreased viability GR00221-A-3 9.98 CDKN2A FGFR3 MYC NRAS
8 Decreased viability GR00221-A-4 9.98 CDKN2A
9 Decreased viability GR00249-S 9.98 FGFR3 MYC
10 Decreased viability GR00301-A 9.98 KRAS
11 Decreased viability GR00381-A-1 9.98 KRAS
12 Decreased viability GR00402-S-2 9.98 MYC
13 Reduced mammosphere formation GR00396-S 9.17 CCND1 CCND3 CD44 KRAS MYC NCAM1

MGI Mouse Phenotypes related to Plasma Cell Leukemia:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.45 BCL10 CCND1 CD38 CD44 CDKN2A FGFR3
2 hematopoietic system MP:0005397 10.43 BCL10 CCND1 CCND3 CD38 CD40 CD44
3 immune system MP:0005387 10.42 BCL10 CCND1 CCND3 CD38 CD40 CD44
4 homeostasis/metabolism MP:0005376 10.41 CCND1 CCND3 CD38 CD40 CD44 CDKN2A
5 behavior/neurological MP:0005386 10.4 CCND1 CCND3 CD44 CDKN2A FGFR3 IL6
6 endocrine/exocrine gland MP:0005379 10.39 BCL10 CCND1 CCND3 CD38 CD40 CD44
7 growth/size/body region MP:0005378 10.38 CCND1 CCND3 CD44 CDKN2A FGFR3 ICAM1
8 cardiovascular system MP:0005385 10.32 CCND1 CCND3 CD44 CDKN2A ICAM1 IL6
9 mortality/aging MP:0010768 10.31 BCL10 CCND1 CCND3 CD44 CDKN2A FGFR3
10 digestive/alimentary MP:0005381 10.3 CCND1 CD44 CDKN2A FGFR3 ICAM1 IL6
11 integument MP:0010771 10.22 CCND1 CD44 CDKN2A FGFR3 ICAM1 IL6
12 neoplasm MP:0002006 10.22 CCND1 CCND3 CD44 CDKN2A FGFR3 ICAM1
13 nervous system MP:0003631 10.21 BCL10 CCND1 CD40 CD44 CDKN2A FGFR3
14 craniofacial MP:0005382 10.17 CCND1 FGFR3 ITGB1 KRAS MAF MYC
15 liver/biliary system MP:0005370 10.06 CCND3 CD44 CDKN2A IL6 ITGB1 KRAS
16 normal MP:0002873 9.97 CCND1 CCND3 CD40 CD44 FGFR3 ITGB1
17 respiratory system MP:0005388 9.81 CCND1 CCND3 CD44 CDKN2A FGFR3 IL6
18 pigmentation MP:0001186 9.73 CD44 CDKN2A ITGB1 KRAS MYC NRAS
19 skeleton MP:0005390 9.7 CCND1 CD40 CD44 CDKN2A FGFR3 IL6
20 vision/eye MP:0005391 9.44 CCND1 CCND3 CD44 CDKN2A FGFR3 ICAM1

Drugs & Therapeutics for Plasma Cell Leukemia

Drugs for Plasma Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Hematinics Phase 3
2 Epoetin alfa Phase 3 113427-24-0
3
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
4
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
5
leucovorin Approved Phase 2 58-05-9 6006 143
6
Carmustine Approved, Investigational Phase 2 154-93-8 2578
7
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
8
Etoposide Approved Phase 2 33419-42-0 36462
9
Ondansetron Approved Phase 2 99614-02-5 4595
10
Mesna Approved, Investigational Phase 2 3375-50-6 598
11
Daratumumab Approved Phase 2 945721-28-8
12
Elotuzumab Approved Phase 2 915296-00-3
13
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
14
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
15
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
16
Gemcitabine Approved Phase 2 95058-81-4 60750
17
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
18
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
19
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
20
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
21
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
22 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
23
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
24
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
25
tannic acid Approved Phase 2 1401-55-4
26
Promethazine Approved, Investigational Phase 2 60-87-7 4927
27
Acetaminophen Approved Phase 2 103-90-2 1983
28
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
29
Allopurinol Approved Phase 2 315-30-0 2094
30
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
31
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
32
Sodium citrate Approved, Investigational Phase 2 68-04-2
33
Ixazomib Approved, Investigational Phase 2 1072833-77-2
34
Pomalidomide Approved Phase 2 19171-19-8
35
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
36
Mycophenolic acid Approved Phase 2 24280-93-1 446541
37
Venetoclax Approved, Investigational Phase 1, Phase 2 1257044-40-8 49846579
38
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
39
Fluticasone Approved, Experimental Phase 2 90566-53-3 62924
40
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
41
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
42
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
43
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
44
Busulfan Approved, Investigational Phase 2 55-98-1 2478
45
Iron Approved, Experimental Phase 2 15438-31-0, 7439-89-6 27284 23925
46
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
47
Pegaspargase Approved, Investigational Phase 2 130167-69-0
48
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
49
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
50
Glycine Approved, Nutraceutical, Vet_approved Phase 2 56-40-6 750

Interventional clinical trials:

(show top 50) (show all 92)
# Name Status NCT ID Phase Drugs
1 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
2 The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial Completed NCT00003341 Phase 3
3 Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia Unknown status NCT01328236 Phase 2 Bortezomib;Liposome doxorubicin;Dexamethasone
4 Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies Unknown status NCT01435720 Phase 1, Phase 2
5 Phase II Trial of Fludarabine Combined With Intravenous Thiotepa and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Lymphatic Malignancies Including Multiple Myeloma, Non Hodgkin's, Hodgkin Lymphoma and CLL Unknown status NCT02507479 Phase 2 Thiotepa
6 Therapeutic Efficacy of Wilms Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Myeloid Malignancies and Multiple Myeloma: A Phase II Trial Unknown status NCT00965224 Phase 2
7 Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70: Phase II Multicentre Study Completed NCT02858999 Phase 2 PAD-VCD
8 An Evaluation of Bortezomib (VelcadeR ) Followed by High-Dose Melphalan and Bortezomib (VelcadeR) as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants in Patients With Primary Refractory Multiple Myeloma and Plasma Cell Leukemia Completed NCT00307086 Phase 2 Bortezomib;Melphalan
9 A Pilot Study of Lenalidomide and Dexamethasone in Patients With Primary Plasma Cell Leukemia Completed NCT01553357 Phase 2 Lenalidomide, dexamethasone
10 A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00821249 Phase 1, Phase 2 ARRY-520, KSP(Eg5) inhibitor; intravenous;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;Dexamethasone, steroid; oral
11 Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Completed NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
12 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
13 Allogeneic Non-Myeloablative Stem Cell Transplantation Using Fludarabine and Melphalan Conditioning Regimen for Chronic Lymphocytic Leukemia, Lymphoma, and Multiple Myeloma Completed NCT00772811 Phase 2 Flu-Mel
14 An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma Completed NCT01063907 Phase 1, Phase 2 KW-2478;Bortezomib
15 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
16 Allogeneic Bone Marrow Transplantation for Patients With Chronic Myelogenous Leukemia in the Chronic Phase or Multiple Myeloma Completed NCT00004181 Phase 2 busulfan;cyclophosphamide
17 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
18 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
19 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
20 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
21 Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial Completed NCT00027820 Phase 1, Phase 2 Fludarabine Phosphate;Cyclosporine;Mycophenolate Mofetil
22 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
23 A Phase I-II Study to Evaluate the Safety, Tolerability and Anti-Disease Activity of the Aminopeptidase Inhibitor, CHR-2797, in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia or Multiple Myeloma Completed NCT00689000 Phase 1, Phase 2 CHR-2797 (tosedostat): Aminopeptidase inhibitor
24 A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies in Remission From HLA Partially-Matched Related Donors Completed NCT01350245 Phase 2 Cyclophosphamide;Mycophenolate Mofetil (MMF);Tacrolimus
25 Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen Completed NCT00309842 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
26 Unrelated or Partially Matched Allogeneic Donor Stem Cells for Lymphoma, Myeloma, and Chronic Lymphocytic Leukemia Completed NCT00612716 Phase 2 busulfan;cyclophosphamide
27 Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma Recruiting NCT01729091 Phase 2 Lenalidomide;Melphalan
28 Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma Recruiting NCT02506959 Phase 2 Busulfan;Gemcitabine Hydrochloride;Melphalan;Panobinostat
29 MUK Nine b: OPTIMUM. A Phase II Study Evaluating Optimised Combination of Biological Therapy in Newly Diagnosed High Risk Multiple Myeloma and Plasma Cell Leukaemia. Recruiting NCT03188172 Phase 2 Cyclophosphamide;Bortezomib;Lenalidomide;Daratumumab;Dexamethasone;Melphalan;Filgrastim
30 A Phase I-IIa Trial to Assess the Safety and Antitumor Activity of Autologous CD44v6 CAR T-cells in Acute Myeloid Leukemia and Multiple Myeloma Expressing CD44v6 Recruiting NCT04097301 Phase 1, Phase 2 MLM-CAR44.1 T-cells, cyclophosphamide and fludarabine from -5 to -3
31 Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases Recruiting NCT03314974 Phase 2
32 Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen Recruiting NCT02722668 Phase 2 Fludarabine;Cyclophosphamide;MMF;Sirolimus
33 A Phase I-II Open-label Study of Reduced Intensity-allogeneic Transplant of ECT-001 (UM171/ Fed-batch Culture System) Expanded Cord Blood in Patients With High-risk Multiple Myeloma Recruiting NCT03441958 Phase 1, Phase 2
34 Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source Recruiting NCT01028716 Phase 2 Cyclophosphamide;Fludarabine Phosphate;Mycophenolate Mofetil;Tacrolimus;Fludarabine
35 Personalized NK Cell Therapy in Cord Blood Transplantation Recruiting NCT02727803 Phase 2 Busulfan;Clofarabine;Cyclophosphamide;Fludarabine Phosphate;Melphalan
36 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32] Recruiting NCT02661035 Phase 2 Allopurinol;Fludarabine;Cyclophosphamide;ATG;Tacrolimus;MMF
37 Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia Active, not recruiting NCT02547662 Phase 2 Dexamethasone;Ixazomib Citrate;Pomalidomide
38 Phase II Study of Shortened-duration Tacrolimus Following Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Malignancies That Are Challenging to Engraft Active, not recruiting NCT02556931 Phase 2 Fludarabine;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
39 A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Japanese Subjects With Hematological Malignancies Active, not recruiting NCT02265731 Phase 1, Phase 2 azacitadine;venetoclax;rituximab / IDEC-C2B8;rituximab / IDEC-C2B8
40 Adoptive Immunotherapy in Patients With Relapsed Hematological Malignancy: Effect of Duration and Intensity of Early GVHD Prophylaxis on Long-Term Clinical Outcomes Active, not recruiting NCT02593123 Phase 2 mycophenolate mofetil
41 A Phase II, Open-label Study of Bortezomib Following Nonmyeloablative Allogeneic Stem Cell Transplant in Patients With High-risk Multiple Myeloma Active, not recruiting NCT02308280 Phase 2 Bortezomib following nonmyeloablative allogeneic transplant
42 Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen Terminated NCT00615589 Phase 2 Fludarabine/Busulfan x 4 days
43 Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma Terminated NCT01658904 Phase 1, Phase 2 Carfilzomib;Melphalan;Filgrastim
44 Phase II Pilot Efficacy Trial of the Combination Regimen Oncaspar/Doxil/Decadron (ODD) in Patients With Refractory Lymphoid Malignancies Terminated NCT00837200 Phase 2 Oncaspar, Doxil, Decadron
45 Deferasirox Treatment and Labile Plasma Iron in Iron Overloaded Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01159067 Phase 2 deferasirox
46 A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma Terminated NCT00648739 Phase 1, Phase 2 Samalizumab
47 Phase I-II Single Cycle Melphalan/Total Marrow Irradiation (TMI) and Autologous Stem Cell Transplantation (ASCT) Followed by Maintenance in Patients With High-Risk Myeloma and/or Poor Response to Induction Therapy Within 12 Months of Diagnosis Withdrawn NCT03100877 Phase 1, Phase 2 Cyclophosphamide;Lenalidomide;Melphalan
48 Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma Whose Disease Has Been Controlled With Chemotherapy: Rituximab Anti-CD20 Monoclonal Antibody or Interferon Alpha 2-b as Maintenance Therapy Withdrawn NCT00004040 Phase 2
49 A Phase I Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies Unknown status NCT00988013 Phase 1
50 Phase I Study of an Oncofetal Antigen ("OFA") Multi-Peptide Immunotherapy ("BBMPI03") in Subjects With Hematologic Cancer Unknown status NCT02240537 Phase 1 Sargramostim;BB-MPI-03;Montanide

Search NIH Clinical Center for Plasma Cell Leukemia

Cochrane evidence based reviews: leukemia, plasma cell

Genetic Tests for Plasma Cell Leukemia

Anatomical Context for Plasma Cell Leukemia

MalaCards organs/tissues related to Plasma Cell Leukemia:

40
Bone, Bone Marrow, Myeloid, B Cells, T Cells, Testes, Nk Cells

Publications for Plasma Cell Leukemia

Articles related to Plasma Cell Leukemia:

(show top 50) (show all 894)
# Title Authors PMID Year
1
Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. 54 61
18231917 2008
2
Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells. 54 61
12017294 2002
3
Analysis of p73 and p53 gene deletions in multiple myeloma. 54 61
10602435 1999
4
The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. 61 54
9844928 1998
5
Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma. 61 54
9369432 1997
6
Overexpression of PRAD1/cyclin D1 in plasma cell leukemia with t(11;14)(q13;q32). 61 54
9220667 1997
7
Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. 61 54
7524765 1994
8
Expression of multiple beta 1 integrins on circulating monoclonal B cells in patients with multiple myeloma. 54 61
7686332 1993
9
The establishment of an interleukin-6-dependent myeloma cell line (FLAM-76) carrying t(11;14)(q13;q32) chromosome abnormality from an aggressive nonsecretory plasma cell leukemia. 54 61
1516003 1992
10
Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. 54 61
1540875 1992
11
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. 54 61
1715218 1991
12
In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. 61 54
2060582 1991
13
Identification of MicroRNAs With In Vivo Efficacy in Multiple Myeloma-related Xenograft Models. 61
32576578 2020
14
Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. 61
32129510 2020
15
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. 61
32555163 2020
16
Secondary Plasma Cell Leukemia: A Case Report. 61
32577333 2020
17
Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis. 61
32401087 2020
18
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. 61
31969333 2020
19
Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study 61
31769277 2020
20
A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab. 61
32318778 2020
21
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. 61
32313109 2020
22
A unique case of relapse of plasma cell leukemia in the vitreous humor. 61
32353698 2020
23
Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature. 61
32321588 2020
24
Multiple Myeloma in the Time of COVID-19. 61
32305989 2020
25
MYC amplification on double minute chromosomes in plasma cell leukemia with double IGH/CCND1 fusion genes. 61
32035866 2020
26
[Treatment of early relapsed plasma cells leukemia after unrelated bone marrow transplant with KRD (carfilzomib, lenalidomide and dexamethasone): a case report.] 61
32157264 2020
27
The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. 61
31709578 2020
28
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT. 61
31832752 2020
29
First reported case of leukocytapheresis in plasma cell leukemia. 61
31682280 2020
30
[Pomalidomide/cyclophosphamide/dexamethasone combination therapy for relapsed/refractory multiple myeloma accompanied by extramedullary lesions]. 61
32023597 2020
31
Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions. 61
32391000 2020
32
Roundtable: How I treat a newly diagnosed patient with high-risk myeloma. 61
31808841 2019
33
A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia. 61
31865846 2019
34
Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia. 61
31628518 2019
35
Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background. 61
31748515 2019
36
Plasma cell leukemia with plasmablastic morphology in a dog. 61
31609183 2019
37
Primary Plasma Cell Leukemia: A Retrospective Study of a Rare Disease From Tertiary Cancer Centre From India. 61
31741616 2019
38
A primitive plasma cell leukemia with immunoglobulin (Ig) E. 61
31512579 2019
39
PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation. 61
31383640 2019
40
Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. 61
31201134 2019
41
Primary plasma cell leukemia: A case report and review of the literature. 61
31534731 2019
42
Oligosecretory Primary Plasma Cell Leukemia with Atypical Morphological Abnormality. 61
30996175 2019
43
Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. 61
30446740 2019
44
Transudative myelomatous pleurisy revealing pleural localization of primary plasma cell leukemia. 61
30907376 2019
45
An update on biology, diagnosis and treatment of primary plasma cell leukemia. 61
30905220 2019
46
Plasma cell leukemia - one in a million: A case report. 61
30949445 2019
47
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. 61
30332496 2019
48
IgM plasma cell myeloma in the era of novel therapy: a clinicopathological study of 17 cases. 61
30266252 2019
49
Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14). 61
30370955 2019
50
[Successful treatment with lenalidomide-containing regimen of plasma cell leukemia accompanied by meningeal involvement]. 61
31839633 2019

Variations for Plasma Cell Leukemia

Expression for Plasma Cell Leukemia

Search GEO for disease gene expression data for Plasma Cell Leukemia.

Pathways for Plasma Cell Leukemia

Pathways related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 NRAS NCAM1 MYC KRAS ITGB1 IRF4
2
Show member pathways
13.87 NRAS MYC KRAS ITGB1 IL6 FGFR3
3
Show member pathways
13.73 NRAS MYC KRAS ITGB1 IL6 FGFR3
4
Show member pathways
13.59 NRAS MYC KRAS ITGB1 IL6 IFNA1
5
Show member pathways
13.46 NRAS KRAS ITGB1 IL6 FGFR3 CD40
6
Show member pathways
13.1 NRAS MYC KRAS IL6 IFNA1 CD40
7
Show member pathways
12.97 NRAS MYC KRAS ITGB1 IL6 IFNA1
8
Show member pathways
12.93 NRAS MYC KRAS IL6 IFNA1 ICAM1
9
Show member pathways
12.91 NRAS MYC KRAS ITGB1 CDKN2A CCND1
10
Show member pathways
12.89 IL6 IFNA1 ICAM1 CD40 CCND1
11
Show member pathways
12.88 NRAS NCAM1 MYC KRAS ITGB1 IRF4
12
Show member pathways
12.81 NRAS MYC KRAS CDKN2A CCND1
13
Show member pathways
12.79 TP73 MYC IL6 IFNA1 ICAM1 CD44
14
Show member pathways
12.75 TP73 NRAS MYC KRAS IRF4 CDKN2A
15
Show member pathways
12.73 NRAS KRAS ITGB1 CCND3 CCND1
16
Show member pathways
12.66 NRAS KRAS IRF4 IL6 BCL10
17
Show member pathways
12.65 NRAS MYC KRAS IL6 FGFR3 CCND1
18
Show member pathways
12.64 NRAS MYC KRAS ITGB1 IL6
19 12.6 NCAM1 IRF4 IFNA1 CD44 CD38 BCL10
20
Show member pathways
12.58 NCAM1 IRF4 IFNA1 ICAM1 CD44
21 12.58 NRAS MYC KRAS ITGB1 IL6 IFNA1
22
Show member pathways
12.53 NRAS MYC KRAS ITGB1 CCND1
23 12.5 NRAS MYC MIR181A1 KRAS FGFR3 CDKN2A
24
Show member pathways
12.48 NRAS KRAS CD40 BCL10
25
Show member pathways
12.48 NRAS KRAS ITGB1 FGFR3
26
Show member pathways
12.46 NRAS MYC KRAS IRF4 BCL10
27
Show member pathways
12.45 NRAS MYC KRAS IL6 IFNA1 CCND3
28
Show member pathways
12.44 NRAS KRAS ITGB1 IL6 FGFR3
29
Show member pathways
12.42 TP73 MYC MIR181A1 CDKN2A CCND3 CCND1
30 12.41 MYC CDKN2A CCND3 CCND1
31 12.35 NRAS KRAS CDKN2A CCND3 CCND1
32 12.32 MYC MAF IL6 CD40
33 12.31 NRAS MYC KRAS ITGB1 CD44 CCND1
34
Show member pathways
12.3 MYC KRAS IRF4 IL6 IFNA1 FGFR3
35
Show member pathways
12.28 MYC CD44 CCND3 CCND1
36
Show member pathways
12.28 NRAS KRAS ITGB1 CD44
37
Show member pathways
12.28 MYC CDKN2A CCND3 CCND1
38
Show member pathways
12.27 NRAS KRAS IL6 BCL10
39 12.24 MYC KRAS IL6 CCND1
40
Show member pathways
12.22 NRAS MYC KRAS ITGB1 FGFR3 CCND3
41 12.21 TP73 MYC CCND3 CCND1
42 12.18 NCAM1 ITGB1 ICAM1 CD40
43 12.16 NRAS MYC KRAS FGFR3
44
Show member pathways
12.14 NRAS KRAS IL6 CCND1
45 12.12 NCAM1 MYC ITGB1 IL6
46 12.11 NRAS MYC KRAS IL6 CDKN2A CCND3
47 12.08 NCAM1 ITGB1 ICAM1 CD44
48 12.07 NRAS MYC KRAS CCND1
49 12.06 MYC IL6 ICAM1 CCND1
50 12.04 NCAM1 IL6 CD44 CD38

GO Terms for Plasma Cell Leukemia

Cellular components related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.56 KRAS ITGB1 ICAM1 BCL10
2 focal adhesion GO:0005925 9.55 KRAS ITGB1 ICAM1 FGFR3 CD44
3 host cell nucleus GO:0042025 9.26 MYC MAF CCND3 CCND1
4 cell surface GO:0009986 9.17 NCAM1 ITGB1 ICAM1 FGFR3 CD44 CD40

Biological processes related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.09 TP73 MYC MAF IRF4 IL6 CDKN2A
2 positive regulation of gene expression GO:0010628 9.99 MYC MAF KRAS IL6 CDKN2A
3 positive regulation of transcription, DNA-templated GO:0045893 9.87 TP73 MYC IRF4 IL6 CDKN2A CD38
4 positive regulation of apoptotic process GO:0043065 9.85 TP73 ITGB1 IL6 CDKN2A BCL10
5 positive regulation of protein phosphorylation GO:0001934 9.84 KRAS CD40 CCND3 CCND1
6 cellular response to lipopolysaccharide GO:0071222 9.83 IL6 ICAM1 CD40 BCL10
7 response to drug GO:0042493 9.83 TP73 MYC ICAM1 CD38 CCND1
8 MAPK cascade GO:0000165 9.8 NRAS NCAM1 MYC KRAS FGFR3
9 viral entry into host cell GO:0046718 9.78 NCAM1 ITGB1 ICAM1
10 cellular response to interleukin-1 GO:0071347 9.77 MYC ICAM1 CD40
11 positive regulation of kinase activity GO:0033674 9.76 FGFR3 CD44 BCL10
12 Ras protein signal transduction GO:0007265 9.75 NRAS KRAS CDKN2A
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.74 IL6 FGFR3 CD40
14 response to glucocorticoid GO:0051384 9.73 KRAS IL6 CCND1
15 G1/S transition of mitotic cell cycle GO:0000082 9.67 MYC ITGB1 CDKN2A CCND1
16 interferon-gamma-mediated signaling pathway GO:0060333 9.56 NCAM1 IRF4 ICAM1 CD44
17 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.55 KRAS IL6 ICAM1 CD40 BCL10
18 T-helper 17 cell lineage commitment GO:0072540 9.51 IRF4 IL6
19 positive regulation of cell proliferation GO:0008284 9.5 MYC KRAS ITGB1 IL6 FGFR3 CD38
20 CD40 signaling pathway GO:0023035 9.49 ITGB1 CD40
21 re-entry into mitotic cell cycle GO:0000320 9.48 MYC CCND1
22 cytokine-mediated signaling pathway GO:0019221 9.23 MYC KRAS ITGB1 IRF4 IL6 IFNA1

Molecular functions related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.65 TP73